Drug Profile
Domvanalimab - Arcus Biosciences
Alternative Names: AB 154; GS-0154Latest Information Update: 17 Apr 2024
Price :
$50
*
At a glance
- Originator Abmuno Therapeutics
- Developer Arcus Biosciences; AstraZeneca; Gilead Sciences; University of Texas Southwestern Medical Center; Yale University
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants; T lymphocyte stimulants; TIGIT protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Gastrointestinal cancer; Non-small cell lung cancer
- Phase II Liver cancer
- Phase I/II Cancer; Pancreatic cancer
- Phase I Glioblastoma
Most Recent Events
- 16 Apr 2024 Arcus Biosciences and Gilead plans a phase III STAR-131 trial for Non small cell lung cancer
- 29 Jan 2024 Arcus Biosciences plans a phase III trial in Non-small cell lung cancer in the US, Hong Kong, Malaysia, Philippines, Slovakia, South Africa, Thailand, Vietnam, Spain, Greece, and Ireland (IV) (NCT04736173)
- 29 Jan 2024 Arcus Biosciences terminates a phase III trial for Non-small cell lung cancer in the US, Hong Kong, Malaysia, Philippines, Slovakia, South Africa, Thailand, Vietnam, Spain, Greece, and Ireland (IV) based on strategic prioritization to advance and potentially accelerate the Phase 3 studies STAR-121 and STAR-221 (NCT04736173)